Clinical Trial

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated December 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study aimed to evaluate the efficacy, safety, tolerability, feasibility of surgery, and incidence of preoperative and postoperative complications of atezolizumab in combination with platinum-based chemotherapy with resectable stage II-IIIB non-small cell lung cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-03-16; most recent amendment 2024-09-17.
Status change: Not Yet Recruiting → Recruiting 2023-02-28
Trial Details
NCT Number NCT05295212
Lead Sponsor Hunan Province Tumor Hospital
Conditions Non Small Cell Lung Cancer
Enrollment 120 participants
Start Date 2023-02-01
Primary Completion 2024-12-01 (estimated)
Study Completion 2025-07-01 (estimated)
Updated on ClinicalTrials.gov 2024-09-19